Thinness: Clinical Trials

29 trials for Thinness, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 completed. 29 Phase 2, 4 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 229Completed 29
Phase 34Completed 4
Phase 11Completed 1

Follow Thinness: new trials by email Literature Review of Thinness trials Research Report on Thinness

Trials (filtered) newest first · largest first

All 29 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
ponsegromab, Placebo for ponsegromab - Non-small Cell Lung Cancer, Pancreatic Cancer
Phase 2CompletedPfizer1872022-11-212026-06-03
Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.
Mirtazapine, Megestrol - Cachexia; Cancer, Anorexia
Phase 2CompletedUniversity of Sao Paulo522019-03-262023-07-07
Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)
GSK2881078, Matching Placebo - Cachexia
Phase 2CompletedGlaxoSmithKline972018-02-282020-07-15
Reformulated F75 Milk to Treat Severe Acute Malnutrition
Standard F75 Milk, Modified F75 Milk - Malnutrition, Diarrhoea
Phase 2 / Phase 3CompletedUniversity of Oxford8422014-12-012016-04-14
Impact of Nutritional Intervention in Indian Female Cancer Cachexia Patients
Improved Atta, Nutritional counseling, Physical activity counseling - Cachexia, Cancer
Phase 2CompletedUniversity of Westminster622013-12-012015-01-30
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
Placebo, BYM338 - Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
Phase 2CompletedNovartis Pharmaceuticals672012-09-012016-05-03
Complementary Food Supplements for Reducing Childhood Undernutrition
Wheat Soy Blend (WSB++), Chickpea based complementary food supplement, Rice based complementary food supplement - Stunting, Wasting
Phase 2 / Phase 3CompletedJohns Hopkins Bloomberg School of Public Health54492012-09-012018-08-24
Soy-Ready to Use Therapeutic Food (RUTF) in Severely Malnourished Children
Soy-based RUTF (in double blind design) - Severe Acute Malnutrition, Severe Wasting
Phase 2 / Phase 3CompletedInternational Centre for Diarrhoeal Disease Research, Bangladesh2602012-07-012017-09-25
Effectiveness of Nutritional Products to Treat Moderate Acute Malnutrition
A daily ration of 40 kcal/kg of body weight during 56 days - Wasting, Moderate Acute Malnutrition
Phase 2CompletedCentre for Food and Nutrition Research, Yaounde812012-02-012013-07-12
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
BYM338 active drug, Placebo - Cachexia
Phase 2CompletedNovartis Pharmaceuticals572011-08-012016-03-02
A Clinical Study With MT-102 in Subjects With Cancer Cachexia
MT-102 - Cancer Cachexia
Phase 2CompletedAkamis Bio872011-04-012014-09-10
Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)
Olanzapine - Amyotrophic Lateral Sclerosis (ALS)
Phase 2 / Phase 3CompletedCharite University, Berlin, Germany402011-03-012024-02-14
Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study
ghrelin - Advanced Cancer, Cachexia
Phase 1 / Phase 2CompletedCantonal Hospital of St. Gallen212009-06-012017-08-01
Pilot Study of APD209 in Cancer Cachexia
APD209 - Cancer-related Cachexia
Phase 2CompletedAcacia Pharma Ltd132009-03-012012-01-13
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
ALD518, Infusion of 0.9% Saline without ALD518 - NSCLC, Fatigue
Phase 2CompletedCSL Behring1242008-09-012020-07-09
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
Placebo comparator, SUN11031 20 μg/kg, SUN11031 40 μg/kg - Cachexia
Phase 2CompletedDaiichi Sankyo2272008-05-152021-01-28
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
GTx-024, Placebo - Cachexia
Phase 2CompletedGTx1592007-05-012014-07-11
Regimen for the Treatment of Cachexia in Subjects With NSCLC
VT-122 low dose, VT-122 high dose - Cachexia
Phase 2CompletedVicus Therapeutics372007-01-012013-01-30
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
RC-1291 HCl - Cancer Cachexia
Phase 2CompletedHelsinn Therapeutics (U.S.), Inc802005-06-012013-09-02
Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss
Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL, Megestrol acetate oral suspension 40 mg/mL - HIV Infections, Cachexia
Phase 2CompletedEndo USA Inc., a Keenova Therapeutics Company632004-12-012017-10-05

Showing 20 of 29. Sign in to see all of them.

Narrower conditions

Cachexia (29)  ·  Anorexia (8)  ·  Neoplasms (5)  ·  HIV Infections (4)  ·  Pulmonary Disease, Chronic Obstructive (4)  ·  Acquired Immunodeficiency Syndrome (3)  ·  Fatigue (3)  ·  Pancreatic Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Colorectal Neoplasms (2)  ·  Emaciation (2)  ·  HIV Wasting Syndrome (2)  ·  Lung Neoplasms (2)  ·  Malnutrition (2)  ·  Muscular Atrophy (2)

Broader conditions

Pathological Conditions, Signs and Symptoms (29)  ·  Signs and Symptoms (29)  ·  Body Weight (28)  ·  Body Weight Changes (28)  ·  Weight Loss (27)  ·  Signs and Symptoms, Digestive (9)  ·  Lung Diseases (8)  ·  Respiratory Tract Diseases (8)  ·  Pathologic Processes (7)  ·  Disease Attributes (6)  ·  Immune System Diseases (6)  ·  Neoplasms by Site (6)  ·  Nutrition Disorders (6)  ·  Nutritional and Metabolic Diseases (6)

Interventions

Megestrol Acetate (5)  ·  Infliximab (2)  ·  Cyproheptadine (1)  ·  Etanercept (1)  ·  GSK2881078 (1)  ·  Gemcitabine (1)  ·  Ghrelin (1)  ·  Megestrol (1)  ·  Mirtazapine (1)  ·  Nutrition Assessment (1)  ·  Olanzapine (1)  ·  Physical Therapy Modalities (1)  ·  Sodium Chloride (1)  ·  Testosterone (1)  ·  Thalidomide (1)

Sponsors

Novartis Pharmaceuticals (2)  ·  Acacia Pharma Ltd (1)  ·  Akamis Bio (1)  ·  Bristol-Myers Squibb (1)  ·  CSL Behring (1)  ·  Cantonal Hospital of St. Gallen (1)  ·  Celgene Corporation (1)  ·  Center for Integrated Rehabilitation and Organ Failure Horn (1)  ·  Centocor, Inc. (1)  ·  Centre for Food and Nutrition Research, Yaounde (1)  ·  Charite University, Berlin, Germany (1)  ·  Charles Drew University of Medicine and Science (1)  ·  Daiichi Sankyo (1)  ·  Endo USA Inc., a Keenova Therapeutics Company (1)  ·  GTx (1)

Countries

United States (15)  ·  India (5)  ·  United Kingdom (5)  ·  Canada (4)  ·  Germany (4)  ·  Poland (3)  ·  Romania (3)  ·  Australia (2)  ·  Bangladesh (2)  ·  Netherlands (2)  ·  Switzerland (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Cameroon (1)

Top investigators

Abu Ahmed Shamim, MS (1)  ·  Alain B Labrique, PhD (1)  ·  Britta Schumacher, PhD (1)  ·  Emiel FM Wouters, PhD, MD (1)  ·  Florian Strasser, PD Dr. MD (1)  ·  Gabriel Fox, MB BChir (1)  ·  Gabriel Medoua Nama, Ph.D. (1)  ·  Hasmot Ali, MPH (1)  ·  Ihab Tewfik, PhD (1)  ·  James A Berkley (1)  ·  Jamie Hayden Von Roenn, MD (1)

Results publications

PMID 17662149, PMID 18257397, PMID 18989154, PMID 21475692, PMID 23499390, PMID 25524795, PMID 27252077, PMID 27680994, PMID 28644348, PMID 30095981, PMID 30184222, PMID 30807589, PMID 31037340, PMID 31775877, PMID 32240304, PMID 32875267, PMID 33154417, PMID 34538239, PMID 36283827, PMID 38500292, PMID 38641716, PMID 39007915, PMID 39282907, PMID 39662676

NIH funding

2017 (1), 2023 (1), U10CA081920 (1)